North America Glioblastoma Multiforme Market Secrets

North America is dominating the Global Glioblastoma Multiforme market in 2019 accounting for a share of about 32.87% and estimated to hold a significant market size over the forecast period (2022-2029). North America has the largest share in the glioblastoma multiforme market, owing to significant market players, increasing healthcare awareness, and FDA approvals for novel drugs. For instance, in October 2019, Denovo Biopharma, a San Diego-based biotech company, was granted the U.S. Food & Drug Administration (FDA) approval for its phase 2b clinical trial evaluating an analytical combination therapy for the treatment of newly diagnosed glioblastoma multiforme patients. Their DB102 treatment was approved for a study to gauge the efficacy in combination with temozolomide (Temodar) and radiation. According to the American Society of Clinical Oncology (ASCO), in 2019, it was expected that an estimated 23,820 adults (13,410 men and 10,410 women) in the United States would be diagnosed with primary cancerous tumors of the brain and spinal cord. Brain tumors account for 85% to 90% of all primary CNS tumors. Thus, growing cancerous tumor cases in the country are driving the market growth in the forecast period.

The mergers, acquisitions, and collaborations by significant players in the North American region also contribute to the market's growth.

For instance, in October 2019, UCLA and Advaxix entered into a collaboration for glioblastoma multiforme (GBM) immunotherapy products. Advaxix, behind this collaboration, aimed to conduct preclinical studies assessing the Lm technology of UCLA in mouse tumor models of GBM. The development of advanced methods of treatment that counter the resistive properties of glioma stem cells is also positively influencing the market growth. Additionally, increasing research and development (R & R&D) activities in molecular biotechnology and gene therapy for cancer and related diseases have facilitated various biological drugs. These drugs assist in diminishing the side effects of the existing treatment methods, thus creating broader acceptance amongst patients. New drug approvals and launches for GBM treatment are expected to drive market growth in the region. For instance, in January 2020, Pfizer launched 'Zirabev' in the U.S. It is a bevacizumab biosimilar to Avastin, approved for the treatment of recurrent glioblastoma multiforme. The FDA approved the biosimilar in June 2019 to treat metastatic or recurrent NSCLC, metastatic colorectal cancer, recurrent glioblastoma multiforme, recurrent/persistent or metastatic cervical cancer, and metastatic renal cell carcinoma. In November 2019, the U.S. FDA accepted Samsung's BLA application for SB8 bevacizumab, a biosimilar to Avastin. If the drug is approved by FDA, it will be available in the U.S. market.

This region leads the market due to governmental and non-governmental support and the presence of vaccine products under the clinical phases for trials to treat GBM. Organizations such as the Brain Tumor Foundation of Canada and the American Brain Tumor Association are involved in raising awareness about glioblastoma multiforme treatment, thus leading to the market's growth forecast period. The presence of the key players for the drugs used for the treatment of GBM also contributed to the expansion of the glioblastoma multiforme market in North America. Furthermore, critical players in the industry are involved in joint ventures and collaborations to develop and commercialize novel drugs to strengthen their position in the global recurrent glioblastoma multiforme treatment market. For instance, in May 2017, DelMar Pharmaceuticals formalized the collaboration agreement with PRA Health Sciences to conduct phase 3 trials of VAL-083 for the treatment of recurrent GBM. PRA Health Sciences is a contract research organization that outsources clinical development services to the pharmaceutical and biotechnology industries. However, current FDA-approved treatments are likely to cause neurotoxicity in patients who might stagger market growth. This treatment is not resistant to DNA modifying agents thus, hampering its growth in the market. 

About Us:

DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within less than a year, we have secured more than 100 unique customers from established organizations all over the world.

For more information:

Sai Kiran

Sales Manager at DataM Intelligence

Email: [email protected]

Tel: +1 877 441 4866

Website: www.datamintelligence.com